| COVID-19: Reflections on trust, tradeoffs, and preparedness D Balog-Way, K McComas Journal of Risk Research, 2020 | 269 | 2020 |
| The Evolving Field of Risk Communication D Balog-Way, K McComas, J Besley Risk Analysis, 2020 | 162 | 2020 |
| Transparency in Europe: a quantitative study F Bouder, D Way, R Löfstedt, D Evensen Risk Analysis 35 (7), 1210-1229, 2015 | 75 | 2015 |
| Transparency and trust in the European pharmaceutical sector: outcomes from an experimental study R Löfstedt, D Way Journal of Risk Research 19 (9), 1082-1103, 2016 | 31 | 2016 |
| Pharmaceutical benefit–risk communication tools: a review of the literature D Way, H Blazsin, R Löfstedt, F Bouder Drug safety 40, 15-36, 2017 | 29 | 2017 |
| Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients D Way, F Bouder, R Löfstedt, D Evensen Journal of Risk Research 19 (9), 1185-1215, 2016 | 28 | 2016 |
| Effects of public trust on behavioural intentions in the pharmaceutical sector: data from six European countries D Balog-Way, D Evensen, R Lofstedt, F Bouder Journal of Risk Research, 2019 | 14 | 2019 |
| Transparency in risk regulation: The case of the European medicines agency DHP Way King's College London, 2017 | 11 | 2017 |
| Transparency of medicines data and safety issues–a European/US study of doctors’ opinions: what does the evidence show? R Löfstedt, D Way, F Bouder, D Evensen Journal of Risk Research 19 (9), 1172-1184, 2016 | 9 | 2016 |
| Pharmaceutical Benefit–Risk Perception and Age Differences in the USA and Germany DHP Balog‑Way, D Evensen, RE Löfstedt Drug safety, 2020 | 4 | 2020 |
| Transparency and trust in the European pharmaceutical sector: a Commentary R Lofstedt, D Way Journal of Risk Research 19 (9), 1120-1128, 2016 | 4 | 2016 |
| Towards an evidence‐informed strategy for communicating lead ammunition risks DHP Balog‐Way, KA McComas, AD Leong, DO Brown, KL Schuler Wildlife Society Bulletin 47 (2), e1445, 2023 | 3 | 2023 |
| Pharmaceutical Benefit-Risk Perception and Older Age: A Pilot Study D Balog-Way, R Lofstedt Therapeutic Innovation & Regulatory Science, 1-13, 2020 | 2 | 2020 |
| Expanding on Behavioral Outcomes in the Risk Information Seeking and Processing Model: Socio-Cognitive Factors Predicting Information Seeking, Sharing, and Discussion AD Leong, KA McComas, DHP Balog-Way, KL Schuler Science Communication 45 (3), 310-336, 2023 | 1 | 2023 |
| OPINIONS ON LEAD AND NONLEAD HUNTING AMMUNITION D Balog-Way, A Leong, K Schuler, D Brown | | 2022 |
| How to Measure the Impact of Pharmacovigilance Activities on Public Health? H Gardarsdottir, A Kant, ML De Bruin, CE Hallgren, G Dal Pan, D Way PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 26, 31-31, 2017 | | 2017 |
| How risks are perceived. Recent research findings D Way, F Bouder, R Löfstedt Clinical Therapeutics 37 (8), e161-e162, 2015 | | 2015 |
Ragnar LofstedtProfessor of Risk Management, King's College London在 kcl.ac.uk 的电子邮件经过验证
